The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
Open accessAbstract
OBJECTIVES: To reanalyse SmithKline Beecham's Study 329 (published by Keller and colleagues in 2001), the primary objective of which was to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar major depression. The reanalysis under the restoring invisible and abandoned trials (RIAT) initiative was done to see whether access to and reanalysis of a full dataset from a randomised controlled trial would have clinically relevant implications for evidence based medicine. DESIGN: Double blind randomised placebo controlled trial. SETTING: 12 North American academic psychiatry centres, from 20 April 1994 to 15 February 1998. PARTICIPANTS: 275 adolescents with major depression of at least eight weeks in duration. Exclusion criteria included a range of comorbid psychiatric and medical disorders and suicidality. INTERVENTIONS: Participants were randomised to eight weeks double blind treatment with paroxetine (20-40 mg), imipramine (200-300 mg), or placebo. MAIN OUTCOME MEASURES: The prespecified primary efficacy variables were change from baseline to the end of the eight week acute treatment phase in total Hamilton depression scale (HAM-D) score and the proportion of responders (HAM-D score ≤8 or ≥50% reduction in baseline HAM-D) at acute endpoint. Prespecified secondary outcomes were changes from baseline to endpoint in depression items in K-SADS-L, clinical global impression, autonomous functioning checklist, self-perception profile, and sickness impact scale; predictors of response; and number of patients who relapse during the maintenance phase. Adverse experiences were to be compared primarily by using descriptive statistics. No coding dictionary was prespecified. RESULTS: The efficacy of paroxetine and imipramine was not statistically or clinically significantly different from placebo for any prespecified primary or secondary efficacy outcome. HAM-D scores decreased by 10.7 (least squares mean) (95% confidence interval 9.1 to 12.3), 9.0 (7.4 to 10.5), and 9.1 (7.5 to 10.7) points, respectively, for the paroxetine, imipramine and placebo groups (P=0.20). There were clinically significant increases in harms, including suicidal ideation and behaviour and other serious adverse events in the paroxetine group and cardiovascular problems in the imipramine group. CONCLUSIONS: Neither paroxetine nor high dose imipramine showed efficacy for major depression in adolescents, and there was an increase in harms with both drugs. Access to primary data from trials has important implications for both clinical practice and research, including that published conclusions about efficacy and safety should not be read as authoritative. The reanalysis of Study 329 illustrates the necessity of making primary trial data and protocols available to increase the rigour of the evidence base.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,526
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Major Depression in Community Adolescents: Age at Onset, Episode Duration, and Time to Recurrence
LEWINSOHN, P. M., CLARKE, G. N., SEELEY, J. R., & ROHDE, P. (1994) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199407000-00006 · Cited by 836
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641
NIMH Treatment of Depression Collaborative Research Program: Background and Research Plan
Elkin, I. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790260103013 · Cited by 520
Beyond significance testing: Statistics reform in the behavioral sciences (2nd ed.).
Kline, R. B. (2013) · doi:10.1037/14136-000 · Cited by 316
Diagnostic and statistical manual of mental disorders, third edition, revised (DSM-III-R)
(1992) · Diagnostic Criteria for Functional Psychoses · doi:10.1017/cbo9780511663208.013 · Cited by 291
FAWCETT, J. A., Epstein, P., Fiester, S. J., Elkin, I., & Autry, J. H. (1987) · PubMed · Cited by 273
Restoring invisible and abandoned trials: a call for people to publish the findings
Doshi, P., Dickersin, K., Healy, D., Vedula, S. S., & Jefferson, T. (2013) · BMJ · doi:10.1136/bmj.f2865 · Cited by 190
Self-citationReanalyses of Randomized Clinical Trial Data
Ebrahim, S., Sohani, Z. N., Montoya, L., Agarwal, A., Thorlund, K., Mills, E. J., & Ioannidis, J. P. A. (2014) · JAMA · doi:10.1001/jama.2014.9646 · Cited by 184
Kline, R. B. (2004) · Cited by 157
Clinical trials and drug promotion: Selective reporting of study 329
Jureidini, J. N., McHenry, L. B., & Mansfield, P. R. (2008) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2008-0426 · Cited by 98
Self-citationMaund, E., Tendal, B., Hróbjartsson, A., Jørgensen, K. J., Lundh, A., Schroll, J. B., & Gøtzsche, P. C. (2014) · BMJ · doi:10.1136/bmj.g3510 · Cited by 89
Hughes, S., Cohen, D., & Jaggi, R. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005535 · Cited by 82
The measurement of behavioral autonomy in adolescence: the autonomous functioning checklist.
Sigafoos, A. D., Feinstein, C., Damond, M., & Reiss, D. (1988) · PubMed · Cited by 70
Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study
McHenry, L. B., & Jureidini, J. N. (2008) · Accountability in Research · doi:10.1080/08989620802194384 · Cited by 67
Self-citationTreasure, T., Monson, K., Fiorentino, F., & Russell, C. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004385 · Cited by 66
Prospective studies of adverse events related to antidepressant discontinuation.
D, M. F. M. (2006) · PubMed · Cited by 52
Defining and achieving recovery from bipolar disorder.
Harvey, P. D. (2006) · PubMed · Cited by 43
Dystonias and dyskinesias of the jaw associated with the use of SSRIs
Fitzgerald, K., & Healy, D. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100308 · Cited by 35
Self-citationConflicted Medical Journals and the Failure of Trust
Jureidini, J. N., & McHenry, L. B. (2011) · Accountability in Research · doi:10.1080/08989621.2011.542683 · Cited by 25
Self-citationRestoring invisible and abandoned trials: a call for people to publish the findings
(2013) · BMJ · doi:10.1136/bmj.f4223 · Cited by 14
Putting GlaxoSmithKline to the test over paroxetine
Doshi, P. (2013) · BMJ · doi:10.1136/bmj.f6754 · Cited by 11
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta‐analyses
IOANNIDIS, J. P. A. (2016) · The Milbank Quarterly · doi:10.1111/1468-0009.12210 · Cited by 1,483
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Best practices in data analysis and sharing in neuroimaging using MRI
Nichols, T. E., Das, S., Eickhoff, S. B., Evans, A. C., Glatard, T., Hanke, M., Kriegeskorte, N., Milham, M. P., Poldrack, R. A., Poline, J.-B., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4500 · Cited by 714
The 52 symptoms of major depression: lack of content overlap among seven common depression scales
Fried, E. I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.019 · Cited by 649
Metadata
- Authors
- Le Noury, J., Nardo, J. M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-09-16
- Volume
- 351
- Pages
- h4320
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2097197321
- Cited by
- 329
- References
- 24
- FWCI
- 31.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.